COVID-19 Vaccination Clinics
We cannot offer Year 11 or Year 12 students Pfizer vaccination - please book with a vaccine hub. Please do not call our very busy reception staff unless you are certain you meet the criteria below.
Pfizer COVID -19 Vaccination Clinics
We are now able to offer Pfizer vaccines and are running regular clinics. We have very limited supply so are currently only offering this vaccine to our regular patients (who have regularly attended the practice in the past 3 years) and are aged 40-59 years old, and patients aged 16-39 only if they meet the following criteria:
Pregnant - past 12 weeks gestation or women who are breastfeeding
NDIS recipient (must provide NDIS plan or other proof)
Carer and reside with a recipient of NDIS (must provide proof)
Person with serious underlying health condition (eg cancer, transplant recipient, congenital heat disease, cochlear implant and must be approved by doctor. Asthma, previous lung infection or mental health conditions are not eligible conditions).
There are no exceptions to these criteria so please do not call our reception staff who are already working very hard.
Only if you meet these criteria please call the practice on 94161348 to be placed on a waiting list. You will be contacted by the practice when a vaccine becomes available. Due to limited vaccine supply wait times are currently at least 6-8 weeks. If you do not meet these criteria please search online for other vaccination hubs that may be able to accept you.
Astra Zeneca COVID -19 Vaccination Clinics
Appointments for our Astra Zeneca COVID-19 vaccination clinics are currently only available for existing patients who have attended the clinics in the past three years, if you are an existing patient and would like to book please do so via our website. You will then be sent a link to a consent form which will need to be read and completed before the vaccination appointment. If you are aged 18-59 you can have the Astra Zeneca vaccine following discussion with the doctor about risks involved. The risk of Thrombocytopenia Thrombosis Syndrome (TTS) is 3 /100,000 in people aged under 50 years. Mortality from TTS in Australia is less than 8% of those affected with improved diagnosis and treatment. Risk of death is 1/million.
Second vaccinations for Astra Zenica can be given after 6 weeks, although optimal time is 12 weeks. An earlier interval will reduce the effectiveness of the vaccination overall however will give you increased protection earlier. You are welcome to discuss this option with your doctor via telehealth if you would like advice of when to have the booster.
Astra Zenica second dose efficacy from symptomatic disease (original strain):
between 6-8 weeks approximately 60%
between 9-11 weeks approximately 64%
12 weeks or longer 81%
A single dose reduces symptomatic infection by 30 %, household transmission by 46-68%, hospitalisation by 71%.
A second dose reduces symptomatic infection/household transmission reduced by 67% and hospitalisation by 92%.
Australian regulators continue to review all the trials and data available to monitor safety of the vaccines.
The vaccines stimulate the body’s immune system to produce antibodies against the virus. None of the ingredients can cause COVID-19 or any other infection.
The vaccine will be injected into your upper arm. A booster dose will be given 12 weeks after the first dose. As with any vaccine it may not protect everyone. It is not yet known how long the vaccine protection will last.
Side Effects usually are mild to moderate and resolve within a few days. These can include:
Commonly: Tenderness, warmth, redness and itch at the injection site.
Headache (50%), fatigue (50%), muscle aches (40%) joint pains (20%)
Uncommonly: Fainting, dizziness.
Rarely: Allergic reaction including skin rash, swelling, difficulty breathing and anaphylaxis
No other vaccines including the influenza vaccination should be given within 7 days of the vaccine so there is no confusion between side effects, and no potential reduction in effectiveness of either vaccine. Influenza vaccination remains highly recommended in 2021 for at risk populations.
Eligible Medical Conditions